Moleculin Biotech, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $5.5M | $5.4M | $5.1M | $3.7M | $3.6M | $3.4M | $4.5M | $4.9M |
| SG&A Expense | $2.1M | $2.5M | $2.4M | $2.1M | $2.1M | $2.5M | $2.2M | $2.2M |
| Operating Income | $-7.6M | $-7.9M | $-7.5M | $-5.9M | $-5.7M | $-5.9M | $-6.6M | $-7.1M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-7.6M | $-12.8M | $15.6M | $-25.4M | $-17.8M | $-5.9M | $-6.6M | $-7.0M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | $-1.40 | $-3.54 | $16.74 | $-0.08 | $-3.19 | $-1.76 | $-20.25 | $-0.21 |
| EPS (Diluted) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Basic) | 5.7M | 4.1M | 1.2M | 335.7M | 5.6M | 3.4M | 1.2M | 33.4M |
| Shares Outstanding (Diluted) | 5.7M | 4.1M | 1.2M | 335.7M | 5.6M | 3.4M | 1.2M | 33.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |